Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
One Percent Rule Checklist For Safer Forex Trading Risk 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
AstraZeneca's suspension of global trials of its coronavirus vaccine dubbed AZD1222 triggered a 2 percent drop in its shares in London and a 12 plunge in the stock price of its Indian unit, AstraZeneca Pharma India Ltd.
The company is developing the AZD1222 vaccine with the University of Oxford.
The suspension, which dimmed the company's prospect of an early rollout, was necessary to review safety data after an unexplained illness in a participant.
AstraZeneca said that the suspension was routine every time there is a potentially unexplained illness in the trials.
The company is working to expedite the review to minimize any potential impact on the trial timeline.
The decision on restarting the trial will be taken by the medical regulator, the MHRA, that would take only days.
According to a New York Times report, citing a person familiar with the situation, the UK-based participant was found to have transverse myelitis, an inflammation that affects the spinal cord and is often sparked by viral infections.
Whether the condition was directly linked to AZD1222 remains unclear.
The AZD1222 has been described by the World Health Organization (WHO) as probably the world’s leading and the most advanced vaccine.
The vaccine is in late-stage clinical trials in the US, the UK, Brazil, and South Africa.
Additional trials are planned in Russia and Japan, targetting up to 50,000 participants globally.
The participant's reaction to AZD1222 has impacted clinical trials by other vaccine makers, which are on the lookout for similar reactions.
